Font: Financial Modeling Prep • Jun 11, 2026
Twist Bioscience (NASDAQ:TWST) is a company in the synthetic biology field, focusing on manufacturing synthetic DNA. It operates in the growing genomics sector, where demand for precision medicine is increasing. This places Twist Bioscience in the spotlight alongside competitors like Pacific Biosciences of California (NASDAQ:PACB) and Myriad Genetics (NASDAQ:MYGN), as highlighted by Zacks Investment Research.
On June 11, 2026, Piper Sandler analyst David Westenberg initiated coverage on Twist Bioscience with an "Overweight" rating. This type of analyst rating suggests that the analyst believes the stock will perform better than the average return of other stocks in its sector over the next 6 to 12 months.
Westenberg also set a price target of $85.00 for the company. A price target is an analyst's projection of a stock's future price. It acts as an estimate of the stock's potential value, which can help investors make informed decisions.
At the time of the rating, Twist Bioscience was trading at $67.77. This price indicates a potential upside, or increase, of 25.42% to reach the new $85.00 target. During the day's trading session, the stock's price has moved between a low of $67.24 and a high of $71.77.
The company currently has a market capitalization of approximately $4.22 billion, which is the total value of all its shares. Over the past 52 weeks, the stock has seen a high of $80.50 and a low of $23.30, with a current trading volume of over 1.14 million shares.
|
ADGM§>
Adagio Medical Holdings, Inc.
|
$0.80
73.91%
|
|
TNMG§>
TNL Mediagene
|
$0.48
33.06%
|
|
ENSC§>
Ensysce Biosciences, Inc.
|
$0.38
37.17%
|
|
PLTR§>
Palantir Technologies Inc.
|
$162.66
29.45%
|
|
SXTC§>
China SXT Pharmaceuticals, Inc.
|
$0.12
60.08%
|
|
NVDA§>
NVIDIA Corporation
|
$211.94
2.56%
|
|
QNME§>
Lakeside Holding Limited
|
$0.69
-37.59%
|
|
AMIX§>
Autonomix Medical, Inc.
|
$19.50
434.25%
|
|
INTC§>
Intel Corp.
|
$100.86
10.84%
|
|
VTGN§>
VistaGen Therapeutics, Inc.
|
$0.30
22.45%
|